Miles D. White, CEO
Thomas C. Freyman, CFO
Mary Sezla, Sr. VP-Global Strategic Mktg. & Svcs.
Stephen R. Fussell, Sr. VP-Human Resources
John M. Leonard, Sr. VP-Pharmaceuticals R&D
Laura J. Schumacher, General Counsel/Exec. VP/Sec.
Richard W. Ashley, Exec. VP-Corp. Dev.
Thomas C. Freyman, Exec. VP-Finance
John C. Landgraf, Exec. VP-Global Nutrition
Richard A. Davis, Exec. VP-Pharmaceuticals/Pres., Abbott Ventures
John M. Capek, Exec. VP-Medical Devices
Edward L. Michael, Exec. VP-Diagnostics Prod.
Miles D. White, Chmn.
Phone:
847-937-6100
Fax:
847-937-9555
Toll-Free:
Address:
100 Abbott Park Rd.
Abbott Park, IL 60064 US
GROWTH PLANS/SPECIAL FEATURES
Abbott Laboratories develops, manufactures and sells healthcare products and technologies ranging from pharmaceuticals to medical devices marketed in over 130 countries. It operates in four segments: pharmaceutical products, diagnostics products, nutritional products and vascular products. The pharmaceutical segment deals with adult and pediatric conditions such as rheumatoid arthritis, HIV, epilepsy and manic depression. The diagnostic products segment deals with a range of medical tests to diagnose infectious diseases, cancer, diabetes and genetic conditions. Products include Humira for the treatment of arthritis, psoriasis and Crohn’s disease; Aluvia, a protease inhibitor for HIV infection; and Synthroid for hypothyroidism. The diagnostic products segment includes diagnostic systems and tests such as the Commander immunoassay system, ARCHITECT chemistry system and i-STAT hematology systems, which are marketed to hospitals, laboratories, physicians’ offices and plasma protein therapeutic companies. The nutritional products segment offers consumer products such as Similac, Ensure, PediaSure and Zone Perfect, as well as feeding devices in healthcare institutions. The vascular products segment consists of coronary, endovascular and vessel closure devices used in the treatment of vascular disease. Products include the Multi-Link Vision coronary metallic stents, Voyager balloon dilatation systems and StarClose vessel closure devices. These products are generally marketed and sold directly to hospitals from Abbot-owned distribution centers and public warehouses. The company’s other products include the FreeStyle line of diabetes products, as well as medical devices for the eye and a line of animal products for the veterinary market. The company operates internationally in Europe, Asia Pacific, Africa, Latin America and the Middle East. In February 2010, the firm acquired Solvay Pharmaceuticals from Belgium-based Solvay SA for $6.2 billion. In September 2010, it acquired Piramal Healthcare Limited's Healthcare Solutions business in India. Employees are offered medical, dental and vision insurance; flexible spending accounts; adoption assistance; an employee assistance program; legal services; tuition assistance; and life insurance.
FINANCIALS: Sales and profits are in thousands of dollars-add 000 to get the full
amount. Yr. 2010 note: Fiscal 2010 results were not available for all companies
at press time.
- 2010 Sales: $35,166,721
- 2009 Sales: $30,764,707
- 2008 Sales: $29,527,552
- 2007 Sales: $25,914,200
- 2006 Sales: $22,476,322
- 2010 Profits: $4,626,172
- 2009 Profits: $5,745,838
- 2008 Profits: $4,880,719
- 2007 Profits: $3,606,300
- 2006 Profits: $1,716,755
Stock Ticker: ABT
Employees: 90000
Fiscal Year Ends: 12/31